# SARS-CoV-2 antibody–dependent enhancement of infection depends on antibody binding to both ACE2 and Fc receptors

**Authors:** Natalia A. Kuzmina, Sivakumar Periasamy, Kritika Kedarinath, Keziah Hernandez, Caroline Atyeo, S. Moses Dennison, Kan Li, Daniel Bedinger, Sharon L. Schendel, Georgia D. Tomaras, Hanif Ali, Galit Alter, Erica Ollmann Saphire, Alexander Bukreyev

PMC · DOI: 10.1172/jci.insight.197773 · JCI Insight · 2026-02-23

## TL;DR

Some SARS-CoV-2 antibodies can enhance infection by binding to ACE2 and immune cell receptors, leading to increased virus spread.

## Contribution

The study reveals that ADE of SARS-CoV-2 depends on antibody binding to both ACE2 and Fc receptors, not just neutralization potency.

## Key findings

- ADE was significantly reduced by blocking ACE2 or Fc receptors.
- Macrophages showed higher susceptibility to ADE compared to other immune cells.
- ADE magnitude depends on an antibody's ability to block spike protein binding to ACE2.

## Abstract

Antibody-dependent enhancement (ADE) of infection is a well-described phenomenon for several viruses, including dengue, Ebola, respiratory syncytial virus, and HIV. ADE occurs when virus-antibody complexes engage Fc receptors (FcRs) and virus-specific receptors, enhancing infection under conditions of incomplete neutralization. The Coronavirus Immunotherapeutic Consortium (CoVIC) assembled a comprehensive dataset of functional properties for over 400 mAbs, enabling direct comparison of neutralization, Fc-mediated functions, receptor binding, and infection of immune cells. Infection rates in most primary human immune cell types were low, with modest increases observed for some mAbs. In contrast, macrophages were more susceptible to SARS-CoV-2 and exhibited substantial ADE with select mAbs. ADE was completely inhibited by FcR blockade and significantly reduced by antibody- or ceftazidime-mediated blocking of angiotensin-converting enzyme 2 (ACE2). Neutralization potency did not correlate with ADE, as both strongly and weakly neutralizing antibodies induced enhancement. Instead, ADE magnitude depended on an antibody’s ability to block spike protein binding to ACE2. Importantly, ADE resulted in productive infection with release of infectious virus. Evaluation of antibodies against the BA.1 (Omicron) variant revealed reduced or lost ADE for most mAbs, with increased ADE observed for several mAbs relative to the USA-WA1/2020 strain.

Some of antibodies induced by SARS-CoV-2 facilitate enhancement of infection which depends on antibody binding to both ACE2 molecule and Fc receptors on immune cells.

## Linked entities

- **Proteins:** ACE2 (angiotensin converting enzyme 2)
- **Chemicals:** ceftazidime (PubChem CID 5481173)
- **Diseases:** SARS-CoV-2 (MONDO:0100096)

## Full-text entities

- **Genes:** S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, FCGR2A (Fc gamma receptor IIa) [NCBI Gene 2212] {aka CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1}, SPTSSB (serine palmitoyltransferase small subunit B) [NCBI Gene 165679] {aka ADMP, C3orf57, SSSPTB}, FCGR1A (Fc gamma receptor Ia) [NCBI Gene 2209] {aka CD64, CD64A, FCG1, FCGR1, FCRI, FcgammaRI}, CEACAM8 (CEA cell adhesion molecule 8) [NCBI Gene 1088] {aka CD66b, CD67, CGM6, NCA-95}, DICER1 (dicer 1, ribonuclease III) [NCBI Gene 23405] {aka DCR1, Dicer, Dicer1e, GLOW, HERNA, K12H4.8-LIKE}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CD14 (CD14 molecule) [NCBI Gene 929], APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}
- **Diseases:** dengue (MESH:D003715), NTD (OMIM:300855), influenza (MESH:D007251), monocytic leukemia (MESH:D007951), viral infection (MESH:D014777), Coronavirus (MESH:D018352), Diseases (MESH:D004194), inflammation (MESH:D007249), weight loss (MESH:D015431), Infection (MESH:D007239), ADE (MESH:C564835), COVID-19 (MESH:D000086382)
- **Chemicals:** ceftazidime (MESH:D002442), mNG (MESH:D008769), paraformaldehyde (MESH:C003043), carbodiimide (MESH:D002234), BA.1 (MESH:C006646), CO2 (MESH:D002245), casirivimab (MESH:C000711487), glycine (MESH:D005998), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (MESH:D005022), sodium acetate (MESH:D019346), Tween-20 (MESH:D011136), 2-(N-morpholino) ethanesulfonic acid (MESH:C004550), PBS (MESH:D007854), neon (MESH:D009356), HCl (MESH:D006851), Ficoll (MESH:D005362), imdevimab (MESH:C000711488), sodium phosphate (MESH:C018279), HEPES (MESH:D006531), CoVIC-113 (-), ethanolamine (MESH:D019856), S (MESH:D013455), NaCl (MESH:D012965), esters (MESH:D004952), N-hydroxysulfosuccinimide (MESH:C035761), E64d (MESH:C108192), Amine (MESH:D000588), dalbavancin (MESH:C469289), EDTA (MESH:D004492), CR3022 (MESH:C000717587), azide (MESH:D001386)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Dengue virus (no rank) [taxon 12637], Severe acute respiratory syndrome-related coronavirus (no rank) [taxon 694009], Feline infectious peritonitis virus (no rank) [taxon 11135], Human immunodeficiency virus 1 (no rank) [taxon 11676], Middle East respiratory syndrome-related coronavirus (no rank) [taxon 1335626], Ebola virus (no rank) [taxon 1570291], Respiratory syncytial virus (no rank) [taxon 12814], Cricetinae (hamsters, subfamily) [taxon 10026], Cricetus cricetus (black-bellied hamster, species) [taxon 10034], Homo sapiens (human, species) [taxon 9606], Ebola virus [taxon 186536], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** S239D, G236A, N297Q, A330L, I332E
- **Cell lines:** Vero E6 — Chlorocebus sabaeus (Green monkey), Spontaneously immortalized cell line (CVCL_0574), HL-CZ — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_WU73), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), BSL-3 — Homo sapiens (Human), Bloom syndrome, Transformed cell line (CVCL_2869), BA.1 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_A651)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956010/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956010/full.md

## References

85 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956010/full.md

---
Source: https://tomesphere.com/paper/PMC12956010